Abstract:IMPORTANCE: Approximately half of newly-diagnosed hepatocellular carcinoma (HCC) cases in the world occur in China, with hepatitis B virus (HBV) infection being the predominant risk factor. Recently, the guidelines for the management of Chinese HCC patients were updated.OBJECTIVE: The past decade has witnessed a great improvement in the management of hepatocellular carcinoma (HCC). This study reviews the recommendations in the 2019 Chinese guidelines and makes comparison with the practices from the Western world.EVIDENCE REVIEW: The updated recommendations on the surveillance, diagnosis, and treatment algorithm of HCC in the 2019 Chinese guidelines were summarized, and comparisons among the updated Chinese guidelines, the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) guidelines were made.FINDINGS: Besides imaging and pathological diagnoses, novel biomarkers like the seven-micro-RNA panel are advocated for early diagnoses and therapeutic efficacy evaluation in the updated Chinese guidelines. The China liver cancer (CNLC) staging system, proposed in the 2017 guidelines, continues to be the standard model for patient classification, with subsequent modifications and updates being made in treatment allocations. Compared to the Barcelona Clinic Liver Cancer (BCLC) system, the CNLC staging system employs resection, transplantation, and transarterial chemoembolization (TACE) for more progressed HCC. TACE in combination with other regional therapies like ablation or with systemic therapies like sorafenib are also encouraged in select patients in China. The systemic treatments for HCC have evolved considerably since lenvatinib, regorafenib, carbozantinib, ramucirumab and immune checkpoint inhibitors (ICIs)were first prescribed as first-line or second-line agents.CONCLUSIONS AND RELEVANCES: Novel biomarkers, imaging and operative techniques are recommended in the updated Chinese guideline. More aggressive treatment modalities are suggested for more progressed HBV-related HCC in China.

Chinese guidelines on the management of ascites in cirrhosis : Chinese Society of Hepatology, Chinese Medical Association

Chinese guidelines on the management of ascites and its related complications in cirrhosis

Chinese Guidelines On The Management Of Liver Cirrhosis (Abbreviated Version)

Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.

[Chinese guidelines on the management of hepatic encephalopathy in cirrhosis (2024)]

Chinese guidelines on management of hepatic encephalopathy in cirrhosis

Progress on Diagnosis and Treatment of Refractoryascites in Patients with Hepatic Failure

Chinese consensus on the management of liver cirrhosis

Guidelines for the Diagnosis and Management of Alcoholic Liver Disease: Update 2010

Guidelines for the Management of Esophagogastric Variceal Bleeding in Cirrhotic Portal Hypertension.

Guidelines for the Management of Cholestatic Liver Diseases (2021)

Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

Guidelines for diagnosis and treatment of chronic gastritis in China (2022, Shanghai)

Chinese Consensus on Clinical Diagnosis and Therapy of Liver Cirrhosis

Chinese Clinical Practice Guidelines for the Prevention and Treatment of Mother-to-Child Transmission of Hepatitis B Virus (version 2024)

Critical Appraisal of Chinese 2017 Guideline on the Management of Hepatocellular Carcinoma.

Focus on Pharmaceutical Care and Progress in Management of Patients with Liver Cirrhosis and Ascites

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Diagnosis and Management of Intraabdominal Infection: Guidelines by the Chinese Society of Surgical Infection and Intensive Care and the Chinese College of Gastrointestinal Fistula Surgeons

Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma